Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden

BACKGROUND: Human monoclonal antibody ustekinumab is a novel Crohn’s disease (CD) treatment blocking pro-inflammatory cytokines interleukin-12 and 23. The study’s objective was to assess cost-effectiveness of ustekinumab in moderate to severely active CD in Sweden. METHODS: A cost-effectiveness mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Hansson-Hedblom, Amanda, Almond, Chrissy, Borgström, Fredrik, Sly, Indeg, Enkusson, Dana, Troelsgaard Buchholt, Anders, Karlsson, Linda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090969/
https://www.ncbi.nlm.nih.gov/pubmed/30123097
http://dx.doi.org/10.1186/s12962-018-0114-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090969/
https://www.ncbi.nlm.nih.gov/pubmed/30123097
http://dx.doi.org/10.1186/s12962-018-0114-y

Ejemplares similares